|  |  |
| --- | --- |
|  | **Table S3.** Associations of implementation of ferritin-guided donation intervals with primary and secondary study outcomes. |
|  |  |  |  | Time since implementation |
| Outcome | Group |  | N | 6-11 months1 | 12-17 months | 18-23 months | 24-29 months | 30-35 months | 36+ months |
| Ferritin (ng/mL, log10) | PRE2 | Coef (95% CI) | 9,683 | 0.01 (-0.02 – 0.04) | **0.06 (0.03 – 0.08)** | **0.07 (0.03 – 0.10)** | **0.09 (0.06 – 0.11)** | **0.10 (0.06 – 0.15)** | **0.14 (0.10 – 0.18)** |
| POST3 | 6,534 | 0.04 (0.00 – 0.07) | **0.09 (0.07 – 0.12)** | **0.11 (0.08 – 0.15)** | **0.14 (0.11 – 0.17)** | **0.19 (0.15 – 0.24)** | **0.22 (0.18 – 0.25)** |
| Males | 15,737 | **0.08 (0.05 – 0.10)** | **0.17 (0.15 – 0.19)** | **0.18 (0.16 – 0.21)** | **0.21 (0.19 – 0.24)** | **0.22 (0.19 – 0.26)** | **0.24 (0.22 – 0.27)** |
| Iron deficiency4 | PRE | OR (95% CI) | 9,683 | 1.08 (0.92 – 1.27) | **0.76 (0.67 – 0.86)** | **0.69 (0.57 – 0.82)** | **0.65 (0.56 – 0.77)** | **0.61 (0.47 – 0.79)** | **0.44 (0.34 – 0.55)** |
| POST | 6,534 | 0.81 (0.64 – 1.01) | **0.59 (0.49 – 0.70)** | **0.45 (0.34 – 0.59)** | **0.41 (0.32 – 0.52)** | **0.24 (0.15 – 0.37)** | **0.19 (0.12 – 0.27)** |
| Males | 15,737 | **0.55 (0.47 – 0.65)** | **0.29 (0.25 – 0.33)** | **0.23 (0.18 – 0.28)** | **0.16 (0.13 – 0.20)** | **0.15 (0.10 – 0.21)** | **0.19 (0.14 – 0.24)** |
| Hemoglobin (g/dL) | PRE | Coef (95% CI) | 11,994 | 0.02 (-0.04 – 0.08) | **0.07 (0.03 – 0.12)** | **0.17 (0.11** **– 0.23)** | **0.16 (0.10 – 0.21)** | 0.03 (-0.05 – 0.10) | **0.17 (0.10 – 0.23)** |
| POST | 7,683 | 0.09 (0.01 – 0.18) | 0.04 (-0.01 – 0.10) | **0.17 (0.09 – 0.25)** | **0.17 (0.10 – 0.24)** | 0.07 (-0.03 – 0.18) | **0.17 (0.08 – 0.25)** |
| Males | 17,919 | **0.14 (0.08 – 0.20)** | **0.21 (0.17 – 0.25)** | **0.32 (0.26 – 0.37)** | **0.31 (0.26 – 0.37)** | **0.29 (0.21 – 0.36)** | **0.37 (0.31 – 0.43)** |
| Hemoglobin deferral5 | PRE | OR (95% CI) | 11,994 | 0.88 (0.67 – 1.15) | 0.81 (0.66 – 0.98) | **0.54 (0.39 – 0.74)** | **0.64 (0.49 – 0.83)** | **0.56 (0.37 – 0.81)** | 0.66 (0.48 – 0.90) |
| POST | 7,683 | 0.89 (0.56 – 1.12) | 0.82 (0.59 – 1.12) | 0.64 (0.36 – 1.04) | **0.46 (0.27 – 0.73)** | 0.78 (0.41 – 1.37) | 0.49 (0.26 – 0.83) |
| Males | 17,919 | 0.80 (0.55 – 1.12) | **0.50 (0.36 – 0.66)** | **0.35 (0.20 – 0.56)** | **0.44 (0.29 – 0.64)** | **0.23 (0.09 – 0.48)** | **0.23 (0.11 – 0.41)** |
| Donor return6 | PRE | OR (95% CI) | 11,994 | 0.90 (0.77 – 1.04) | **0.86 (0.78 – 0.96)** | 0.91 (0.78 – 1.05) | **0.76 (0.67 – 0.88)** | **0.77 (0.65 – 0.92)** | 0.88 (0.76 – 1.03) |
| POST | 7,683 | 1.07 (0.88 – 1.31) | **0.81 (0.71 – 0.93)** | **0.73 (0.61 – 0.89)** | **0.72 (0.61– 0.85)** | 0.74 (0.59 – 0.94) | 0.77 (0.64 – 0.94) |
| Males | 17,919 | 0.85 (0.73 – 0.98) | **0.86 (0.77 – 0.96)** | **0.74 (0.64 – 0.86)** | **0.67 (0.59 – 0.77)** | **0.64 (0.54 – 0.77)** | **0.56 (0.49 – 0.65)** |
| Restless legs syndrome | PRE | OR (95% CI) | 2,140 | 1.58 (0.99 – 2.49) | 0.98 (0.57 – 1.65) | **2.23 (1.34 – 3.63)** | **2.27 (1.46 – 3.50)** |  |  |
| POST | 1,303 | **2.20 (1.42 – 3.41)** | 0.54 (0.28 – 0.97) | 1.14 (0.53 – 2.23) | **2.27 (1.37 – 3.71)** |  |  |
| Males | 3,316 | 1.09 (0.70 – 1.64) | 0.73 (0.45 – 1.14) | **1.80 (1.12 – 2.80)** | 1.49 (1.01 – 2.16) |  |  |
| Pica | PRE | OR (95% CI) | 2,345 | 1.06 (0.29 – 2.18) | 0.75 (0.29 – 1.67) | 1.28 (0.50 – 2.88) | 0.80 (0.29 – 1.86) |  |  |
| POST | 1,465 | 0.53 (0.08 – 2.05) | 1.66 (0.60 – 4.38) | 1.62 (0.25 – 6.31) | 1.93 (0.52 – 5.87) |  |  |
| Males | 3,545 | 0.68 (0.32 – 1.31) | 1.00 (0.55 – 1.72) | 1.11 (0.48 – 2.25) | 0.91 (0.47 – 1.65) |  |  |
| Fatigue7 | PRE | Coef (95% CI) | 2,360 | -0.33 (-1.05 – 0.39) | 0.71 (-0.03 – 1.44) | -0.86 (-1.75 – 0.04) | -0.38 (-1.17 – 0.42) |  |  |
| POST | 1,471 | -0.29 (-1.09 – 0.51) | 0.32 (-0.45 – 1.09) | -0.16 (-1.31 – 1.00) | -0.49 (-1.54 – 0.55) |  |  |
| Males | 3,558 | -0.40 (-0.92 – 0.12) | -0.50 (-1.01 – 0.01) | -0.78 (-1.61 – 0.04) | -0.27 (-0.82 – 0.28) |  |  |
| Cognitive functioning7 | PRE | Coef (95% CI) | 2,342 | 0.14 (-1.35 – 1.64) | -1.46 (-2.94 – 0.03) | -0.92 (-2.62 – 0.77) | 0.87 (-0.82 – 2.56) |  |  |
| POST | 1,464 | 0.87 (-0.77 – 2.51) | 1.08 (-0.50 – 2.67) | 2.59 (-0.06 – 5.23) | 0.86 (-1.12 – 2.84) |  |  |
| Males | 3,534 | 0.05 (-1.04 – 1.13) | 0.81 (-0.29 – 1.90) | -0.59 (-2.14 – 0.96) | -0.24 (-1.38 – 0.90) |  |  |
| Physical health (SF-36)8 | PRE | Coef (95% CI) | 2,398 | -0.04 (-0.76 – 0.68) | 0.32 (-0.39 – 1.04) | 0.11 (-0.79 – 1.00) | -0.64 (-1.47 – 0.19) |  |  |
| POST | 1,468 | -0.33 (-1.32 – 0.66) | -1.12 (-2.14 – -0.09) | -1.01 (-2.57 – 0.54) | 0.78 (-0.43 – 1.98) |  |  |
| Males | 3,582 | -0.43 (-0.98 – 0.12) | -0.47 (-1.00 – 0.07) | -0.35 (-1.07 – 0.37) | -0.12 (-0.64 – 0.40) |  |  |
| Mental health (SF-36)8 | PRE | Coef (95% CI) | 2,404 | -1.25 (-2.25 – -0.24) | -0.04 (-1.01 – 0.92) | -1.29 (-2.90 – 0.32) | -0.98 (-2.14 – 0.18) |  |  |
| POST | 1,476 | -0.25 (-1.20 – 0.79) | 0.30 (-0.75 – 1.34) | -1.37 (-3.16 – 0.42) | 0.06 (-1.13 – 1.24) |  |  |
| Males | 3,595 | 0.10 (-.56 – 0.75) | -0.46 (-1.13 – 0.22) | -0.16 (-1.10 – 0.79) | 0.925 (-1.02 – 0.34) |  |  |
| Warm glow | PRE | OR (95% CI) | 2,167 | 0.99 (0.77 – 1.26) | 1.41 (1.11 – 1.80) | 1.03 (0.75 – 1.40) | 1.06 (0.81 – 1.39) |  |  |
| POST | 1,403 | 0.86 (0.63 – 1.18) | 0.80 (0.60 – 1.07) | 0.43 (0.27 – 0.68) | 0.90 (0.62 – 1.34) |  |  |
| Males | 3,386 | 0.83 (0.67 – 1.02) | 0.97 (0.79 – 1.19) | 0.72 (0.55 – 0.95) | 0.81 (0.65 – 1.00) |  |  |
| Bold text indicates significance at p < 0.008 (Bonferroni correction: 0.05/6) for primary outcomes and p<0.01 (0.05/4) for secondary outcomes; All analyses are scaled and adjusted for age, height, and weight1 Reference group: no implementation and 0-5 months since implementation2 PRE: Premenopausal females (age ≤ 48)3 POST: Postmenopausal females (age > 48)4 Ferritin < 15 ng/mL5 For males ≥ 13.5 g/dL, for females ≥ 12.5 g/dL 6 Within six months of the first allowed date for the next donation, additionally adjusted for whether return should have been during COVID pandemic7 Higher score indicates worse result8 Higher score indicates better result |